...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell cycle >Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
【24h】

Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.

机译：用不同种类的抑制剂克服对易瑞沙/塔雷斯卡的抗药性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Small molecule kinase inhibitors of the epidermal growth factor receptor (EGFR) have recently been found to exhibit clinical efficacy in the setting of nonsmall cell lung cancers that harbor activating EGFR mutations. However, the remissions induced by these drugs (Iressa and Tarceva) are typically short-lived, presumably due to acquired drug resistance. We recently reported findings demonstrating that a distinct class of EGFR inhibitors may overcome some mechanisms of secondary drug resistance in these tumors and may therefore be useful in treating lung cancer patients that initially responded to Iressa or Tarceva and eventually relapsed.
机译：最近发现表皮生长因子受体（EGFR）的小分子激酶抑制剂在具有激活EGFR突变的非小细胞肺癌的治疗中表现出临床功效。但是，这些药物（Iressa和Tarceva）引起的缓解通常是短暂的，大概是由于获得性耐药性所致。我们最近报道的发现表明，一类独特的EGFR抑制剂可能克服了这些肿瘤中继发性耐药的某些机制，因此可能可用于治疗最初对易瑞沙或特罗凯有效并最终复发的肺癌患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号